Category: Access campaign
ASEAN and India urged not to trade away people’s lives in trade agreement
People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India
MSF statement on resumption of EU-India FTA negotiations
MSF responds to India’s first-ever national anti-tuberculosis drug resistance survey
MSF challenges Pfizer’s monopoly on lifesaving pneumonia vaccine in Korea
MSF challenges Gilead’s patent application for hepatitis C combination treatment in China, to bring down prices
MSF: India’s decision to give Pfizer unmerited patent on lifesaving pneumonia vaccine limits access for children globally
MSF secures generic hepatitis C treatment at $120 compared to $147,000 launch price tag
MSF approaches Delhi High Court to challenge unmerited patent grant for pneumonia vaccine
